Shares of Innate Pharma SA (OTCMKTS:IPHYF) experienced a modest decline of 0.2% on Friday, trading at $1.9950. The stock reached a low of $1.9950 during the session, and only 100 shares changed hands, marking a significant drop of 97% from its average volume of 3,675 shares. The previous closing price was $2.00.
Trading patterns indicate that the stock’s fifty-day moving average stands at $2.00, while the two-hundred-day moving average is at $1.78. Such metrics may provide insight into the stock’s performance trends over time.
About Innate Pharma’s Developments
Based in France, Innate Pharma specializes in developing immunotherapies aimed at treating various cancers. Among its notable products is Lacutamab (IPH4102), an anti-KIR3DL2 antibody currently in Phase II clinical trials for cutaneous T-cell lymphoma and peripheral T-cell lymphoma. Additionally, it is being tested for refractory Sézary syndrome.
Another significant product is Monalizumab, an immune checkpoint inhibitor that is undergoing a Phase III clinical trial for advanced solid tumors, including colorectal and lung cancer, as well as head and neck cancer. The company is also developing IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, which is in Phase II trials.
Further, IPH5301, an anti-CD73 antibody aimed at enhancing antitumor immunity, and other NK cell engagers like IPH6401 and IPH6101 are part of its expanding portfolio.
As Innate Pharma continues its clinical trials, the market will closely monitor its stock performance and the potential impact of its therapies on cancer treatment.
For those interested in keeping up with Innate Pharma, a daily email summary of the latest news and analysts’ ratings is available through MarketBeat.com.
